ClinicalTrials.gg
CompletedNCT05035641Updated Oct 4, 2023

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

A Phase 2 interventional study of AND017 and Placebo in Renal Anemia, sponsored by Kind Pharmaceuticals LLC. Completed at 8 sites in 2 countries. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-10-04.

Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
163rd of 395
113 · median 72
Started
2021
with 15 others
Phase 2
109 of 464
9 open now
Registered
394th of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 163rd largest by enrollment of the 395 interventional ones that give a count, is one of 16 that started in 2021, is one of 109 in phase 2, and was the 394th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

Read the detailed description

This is a pilot phase 2, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral AND017 to treat anemia in non-dialysis-dependent chronic kidney disease patients.

03

Conditions studied

  • Renal Anemia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of chronic kidney disease, not receiving dialysis, with an \<60 mL/min/1.73 m2.
  2. Baseline level ≥ 7.5 g/dL and \<10.0 g/dL.
  3. TSAT ≥ 20% or ferritin ≥ 100 ng/mL at screening test
  4. Serum folate and vitamin B12 ≥ lower limit of normal at screening test
  5. and ALT ≤ 3×.
  6. Total ≤ 1.5×ULN.

Key Exclusion Criteria:

  1. Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  2. Anemia that is possibly mainly caused by concurrent disease with inflammatory symptoms
  3. History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent symptomatic gastroparesis despite being on treatment.
  4. bleeding (eg, requiring transfusion or drop in Hb of ≥ 2g/dL) within 4 weeks of first dose; no bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  5. Uncontrolled hypertension defined as patients with hypertension having more than one of three diastolic blood pressure values >95 mmHg and each test at least 5 min apart during the screening assessment.
  6. Concurrent congestive heart failure ( [NYHA] Class III or higher).
  7. History of stroke, , myocardial infarction, thromboembolic event, pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  8. Concurrent anemia due to another cause other than renal anemia
  9. Known hemosiderosis, hemochromatosis or hyper-coagulable condition
  10. Any treatment with a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) within 5 weeks before randomization.
  11. Having received treatment with erythropoiesis stimulating agents, androgenic anabolic steroids, testosterone enanthate, or mepitiostane within 5 weeks before the first dose.
  12. Total bilirubin >1.5xULN, or AST>3xULN, or ALT>3xULN, or ALP>3xULN, or previous or concurrent serious liver disease (acute or active chronic hepatitis, cirrhosis, etc.) thought to be caused by ESAs.
  13. Patients with a history of significant liver disease or active liver disease. Investigators should discuss this with the Medical Monitor for cases where there is doubt about whether to exclude or not.
  1. Patients that have major surgery planned during the study period. 14. Having undergone blood transfusion and/or a surgical procedure within 8 weeks before the screening assessment.
  1. Having undergone a kidney transplantation. 16. History of a seizure disorder or any occurrence of seizures in the past
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    AND017 Dose A

    AND017 will be administrated orally at dose A

    Drug: AND017

  • Experimental
    AND017 Dose B

    AND017 will be administrated orally at dose B

    Drug: AND017

  • Experimental
    AND017 Dose C

    AND017 will be administrated orally at dose C

    Drug: AND017

  • Placebo comparator
    Placebo

    Placebo will be administrated orally

    Drug: Placebo

Interventions

  • DrugAND017

    Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2

  • DrugPlacebo

    Orally, 3 times per week

06

What researchers measure

Primary outcomes

  1. Safety Evaluations

    Incidence of adverse events

    Time frame: Up to 17 weeks

  2. Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing

    Calculate the slope of a linear regression for each patient using all hemoglobin data collected during the Fixed-Dose Period

    Time frame: Up to 5 weeks after dosing

Secondary outcomes

  1. Hb response to treatment during Period 1

    Cumulative percentage of patients with Hb ≥10.0 g/dL

    Time frame: Up to 5 weeks after dosing

  2. Percentage of responder patients

    Responder is defined as a hemoglobin ≥10.0 g/dL and an increase in hemoglobin by ≥1.0 g/dL

    Time frame: Up to 13 weeks after dosing

  3. Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL

    Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL

    Time frame: Up to 13 weeks after dosing

  4. Change from baseline in Hb

    Change from baseline in Hb

    Time frame: Up to 13 weeks after dosing

  5. Change in hemoglobin levels from baseline to the mean of weeks 10-13

    Change in hemoglobin levels from baseline to the mean of weeks 10-13

    Time frame: Baseline and at Week 10, 11, 12, 13, and 14

  6. Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit

    Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit

    Time frame: Up to 13 weeks after dosing

  7. Mean Hb levels at weeks 6-14 including the average of weeks 10-13

    Mean Hb levels at weeks 6-14 including the average of weeks 10-13

    Time frame: Up to 13 weeks after dosing

  8. Cumulative incidence of lack of response over the entire treatment period

    Hb level \< 10.0 g/dL and an increase in hemoglobin from baseline of \< 1 g/dL

    Time frame: Up to13 weeks after dosing

  9. To assess changes in the levels of PD indicator - EPO

    To assess changes in the levels of EPO

    Time frame: Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose

  10. To assess changes in the levels of PD indicator - hepcidin

    To assess changes in the levels of hepcidin

    Time frame: Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose

  11. To assess iron utilization parameter during treatment - transferrin level

    To assess transferrin level during treatment

    Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

  12. To assess iron utilization parameter during treatment - total iron-binding capacity (TIBC)

    To assess TIBC level during treatment

    Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

  13. To assess iron utilization parameter during treatment - transferrin saturation (TSAT)

    To assess TSAT level during treatment

    Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

  14. To assess iron utilization parameters during treatment - ferritin

    To assess ferritin level during treatment

    Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

  15. To assess iron utilization parameters during treatment - serum iron

    To assess serum iron level during treatment

    Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

07

Study locations

8 sites
  • Amicis Research Center
    Northridge, California 91324, United States
  • Clinical Site Partners
    Winter Park, Florida 32789, United States
  • Northwest Louisiana Nephrology
    Shreveport, Louisiana 71101, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Metrolina Nephrology Associates
    Charlotte, North Carolina 28207, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2023, 20 months.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 20 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Sep 5, 2021
StartActual
Oct 18, 2021
Primary completionActual
Jul 5, 2023
CompletionActual
Jul 24, 2023
Last update
Oct 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05035641
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Oct 18, 2021
Primary completion
Jul 5, 2023
Completion
Jul 24, 2023
Last update
Oct 4, 2023

Study contacts

Yusha Zhu, MD PhD
study director · Kind Pharmaceuticals LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion